FDA approves first generic of drug for prevention of HIV and to treat HIV-1

The U.S. Food and Drug Administration has approved the first generic version of Gilead’s Truvada for the treatment of HIV-1, in combination with other antiretroviral agents, and for pre-exposure prophylaxis (PrEP) in combination with safer sex practices to prevent sexually-acquired HIV infection in adults at high risk.

Read more

ViiV Healthcare studies on treating HIV with two drug regimen

ViiV Healthcare, majority-owned by GSK, with Pfizer and Shionogi Limited as shareholders, has announced detailed study results from its phase III programme evaluating the safety and efficacy of switching virologically suppressed patients from a three- or four-drug antiretroviral regimen to a two-drug regimen of dolutegravir (ViiV Healthcare) and rilpivirine (Janssen Sciences Ireland UC).

Read more

Number of AIDS deaths among young Asians doubles over past decade – U.N

The estimated number of adolescents dying of AIDS in the Asia Pacific region has more than doubled since 2005, experts said on Monday, warning of a “hidden epidemic”.

UNICEF urged Asian countries to improve teenagers’ access to testing, saying many young people do not know their HIV status because of parental consent requirements for tests.

Read more